nodes	percent_of_prediction	percent_of_DWPC	metapath
Loratadine—CYP2D6—Fingolimod—multiple sclerosis	0.092	0.121	CbGbCtD
Loratadine—ABCB1—Methylprednisolone—multiple sclerosis	0.0629	0.0828	CbGbCtD
Loratadine—CYP3A4—Fingolimod—multiple sclerosis	0.0585	0.077	CbGbCtD
Loratadine—CYP2C19—Prednisone—multiple sclerosis	0.0472	0.0622	CbGbCtD
Loratadine—ABCB1—Mitoxantrone—multiple sclerosis	0.0459	0.0604	CbGbCtD
Loratadine—ABCB1—Betamethasone—multiple sclerosis	0.0409	0.0538	CbGbCtD
Loratadine—ABCB1—Prednisolone—multiple sclerosis	0.0404	0.0531	CbGbCtD
Loratadine—ABCB1—Prednisone—multiple sclerosis	0.0381	0.0502	CbGbCtD
Loratadine—CYP3A4—Methylprednisolone—multiple sclerosis	0.0377	0.0496	CbGbCtD
Loratadine—CYP2C8—Dexamethasone—multiple sclerosis	0.0352	0.0463	CbGbCtD
Loratadine—CYP2C19—Dexamethasone—multiple sclerosis	0.0295	0.0388	CbGbCtD
Loratadine—CYP3A4—Triamcinolone—multiple sclerosis	0.0286	0.0376	CbGbCtD
Loratadine—CYP3A4—Mitoxantrone—multiple sclerosis	0.0275	0.0362	CbGbCtD
Loratadine—CYP2C9—Dexamethasone—multiple sclerosis	0.0245	0.0323	CbGbCtD
Loratadine—CYP3A4—Betamethasone—multiple sclerosis	0.0245	0.0323	CbGbCtD
Loratadine—CYP3A4—Prednisolone—multiple sclerosis	0.0242	0.0318	CbGbCtD
Loratadine—ABCB1—Dexamethasone—multiple sclerosis	0.0238	0.0313	CbGbCtD
Loratadine—CYP3A4—Prednisone—multiple sclerosis	0.0228	0.0301	CbGbCtD
Loratadine—CYP2D6—Dexamethasone—multiple sclerosis	0.0224	0.0295	CbGbCtD
Loratadine—ABCB1—Methotrexate—multiple sclerosis	0.0191	0.0252	CbGbCtD
Loratadine—CYP3A4—Dexamethasone—multiple sclerosis	0.0143	0.0188	CbGbCtD
Loratadine—Ill-defined disorder—Prednisolone—multiple sclerosis	0.00051	0.00244	CcSEcCtD
Loratadine—Depression—Prednisone—multiple sclerosis	0.000509	0.00244	CcSEcCtD
Loratadine—Angioedema—Prednisolone—multiple sclerosis	0.000502	0.00241	CcSEcCtD
Loratadine—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.000498	0.00239	CcSEcCtD
Loratadine—Malaise—Prednisolone—multiple sclerosis	0.000495	0.00237	CcSEcCtD
Loratadine—Dysgeusia—Triamcinolone—multiple sclerosis	0.000495	0.00237	CcSEcCtD
Loratadine—Nausea—Cladribine—multiple sclerosis	0.000494	0.00237	CcSEcCtD
Loratadine—Syncope—Prednisolone—multiple sclerosis	0.000492	0.00236	CcSEcCtD
Loratadine—Paraesthesia—Mitoxantrone—multiple sclerosis	0.000491	0.00235	CcSEcCtD
Loratadine—Somnolence—Mitoxantrone—multiple sclerosis	0.000486	0.00233	CcSEcCtD
Loratadine—Loss of consciousness—Prednisolone—multiple sclerosis	0.000483	0.00231	CcSEcCtD
Loratadine—Dyspepsia—Mitoxantrone—multiple sclerosis	0.000481	0.0023	CcSEcCtD
Loratadine—Hypertension—Prednisolone—multiple sclerosis	0.000474	0.00227	CcSEcCtD
Loratadine—Fatigue—Mitoxantrone—multiple sclerosis	0.000471	0.00226	CcSEcCtD
Loratadine—Arrhythmia—Betamethasone—multiple sclerosis	0.00047	0.00225	CcSEcCtD
Loratadine—Arrhythmia—Dexamethasone—multiple sclerosis	0.00047	0.00225	CcSEcCtD
Loratadine—Ill-defined disorder—Triamcinolone—multiple sclerosis	0.000469	0.00225	CcSEcCtD
Loratadine—Ill-defined disorder—Methylprednisolone—multiple sclerosis	0.000468	0.00224	CcSEcCtD
Loratadine—Pain—Mitoxantrone—multiple sclerosis	0.000467	0.00224	CcSEcCtD
Loratadine—Constipation—Mitoxantrone—multiple sclerosis	0.000467	0.00224	CcSEcCtD
Loratadine—Alopecia—Dexamethasone—multiple sclerosis	0.000465	0.00223	CcSEcCtD
Loratadine—Alopecia—Betamethasone—multiple sclerosis	0.000465	0.00223	CcSEcCtD
Loratadine—Diarrhoea—Azathioprine—multiple sclerosis	0.000462	0.00222	CcSEcCtD
Loratadine—Discomfort—Prednisolone—multiple sclerosis	0.000462	0.00221	CcSEcCtD
Loratadine—Angioedema—Triamcinolone—multiple sclerosis	0.000461	0.00221	CcSEcCtD
Loratadine—Angioedema—Methylprednisolone—multiple sclerosis	0.00046	0.00221	CcSEcCtD
Loratadine—Malaise—Triamcinolone—multiple sclerosis	0.000455	0.00218	CcSEcCtD
Loratadine—Malaise—Methylprednisolone—multiple sclerosis	0.000454	0.00218	CcSEcCtD
Loratadine—Syncope—Triamcinolone—multiple sclerosis	0.000453	0.00217	CcSEcCtD
Loratadine—Syncope—Methylprednisolone—multiple sclerosis	0.000452	0.00217	CcSEcCtD
Loratadine—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.00045	0.00216	CcSEcCtD
Loratadine—Anaphylactic shock—Prednisolone—multiple sclerosis	0.000448	0.00215	CcSEcCtD
Loratadine—Dizziness—Azathioprine—multiple sclerosis	0.000447	0.00214	CcSEcCtD
Loratadine—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000447	0.00214	CcSEcCtD
Loratadine—Loss of consciousness—Triamcinolone—multiple sclerosis	0.000444	0.00213	CcSEcCtD
Loratadine—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.000443	0.00212	CcSEcCtD
Loratadine—Shock—Prednisolone—multiple sclerosis	0.000441	0.00211	CcSEcCtD
Loratadine—Cough—Triamcinolone—multiple sclerosis	0.000441	0.00211	CcSEcCtD
Loratadine—Tachycardia—Prednisolone—multiple sclerosis	0.000437	0.0021	CcSEcCtD
Loratadine—Hypertension—Triamcinolone—multiple sclerosis	0.000436	0.00209	CcSEcCtD
Loratadine—Hypertension—Methylprednisolone—multiple sclerosis	0.000435	0.00209	CcSEcCtD
Loratadine—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000432	0.00207	CcSEcCtD
Loratadine—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000432	0.00207	CcSEcCtD
Loratadine—Myalgia—Triamcinolone—multiple sclerosis	0.00043	0.00206	CcSEcCtD
Loratadine—Vomiting—Azathioprine—multiple sclerosis	0.00043	0.00206	CcSEcCtD
Loratadine—Myalgia—Methylprednisolone—multiple sclerosis	0.000429	0.00206	CcSEcCtD
Loratadine—Drowsiness—Methotrexate—multiple sclerosis	0.000427	0.00205	CcSEcCtD
Loratadine—Rash—Azathioprine—multiple sclerosis	0.000426	0.00204	CcSEcCtD
Loratadine—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000426	0.00204	CcSEcCtD
Loratadine—Dermatitis—Azathioprine—multiple sclerosis	0.000426	0.00204	CcSEcCtD
Loratadine—Depression—Methotrexate—multiple sclerosis	0.000426	0.00204	CcSEcCtD
Loratadine—Ill-defined disorder—Betamethasone—multiple sclerosis	0.000425	0.00204	CcSEcCtD
Loratadine—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.000425	0.00204	CcSEcCtD
Loratadine—Discomfort—Triamcinolone—multiple sclerosis	0.000425	0.00204	CcSEcCtD
Loratadine—Discomfort—Methylprednisolone—multiple sclerosis	0.000424	0.00203	CcSEcCtD
Loratadine—Headache—Azathioprine—multiple sclerosis	0.000423	0.00203	CcSEcCtD
Loratadine—Dry mouth—Triamcinolone—multiple sclerosis	0.00042	0.00202	CcSEcCtD
Loratadine—Angioedema—Betamethasone—multiple sclerosis	0.000419	0.00201	CcSEcCtD
Loratadine—Angioedema—Dexamethasone—multiple sclerosis	0.000419	0.00201	CcSEcCtD
Loratadine—Immune system disorder—Prednisone—multiple sclerosis	0.000414	0.00198	CcSEcCtD
Loratadine—Malaise—Betamethasone—multiple sclerosis	0.000413	0.00198	CcSEcCtD
Loratadine—Malaise—Dexamethasone—multiple sclerosis	0.000413	0.00198	CcSEcCtD
Loratadine—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000412	0.00198	CcSEcCtD
Loratadine—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000411	0.00197	CcSEcCtD
Loratadine—Syncope—Betamethasone—multiple sclerosis	0.000411	0.00197	CcSEcCtD
Loratadine—Syncope—Dexamethasone—multiple sclerosis	0.000411	0.00197	CcSEcCtD
Loratadine—Arrhythmia—Prednisone—multiple sclerosis	0.00041	0.00196	CcSEcCtD
Loratadine—Shock—Triamcinolone—multiple sclerosis	0.000405	0.00194	CcSEcCtD
Loratadine—Insomnia—Prednisolone—multiple sclerosis	0.000405	0.00194	CcSEcCtD
Loratadine—Alopecia—Prednisone—multiple sclerosis	0.000405	0.00194	CcSEcCtD
Loratadine—Shock—Methylprednisolone—multiple sclerosis	0.000405	0.00194	CcSEcCtD
Loratadine—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000404	0.00193	CcSEcCtD
Loratadine—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000403	0.00193	CcSEcCtD
Loratadine—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000403	0.00193	CcSEcCtD
Loratadine—Loss of consciousness—Betamethasone—multiple sclerosis	0.000403	0.00193	CcSEcCtD
Loratadine—Epistaxis—Methotrexate—multiple sclerosis	0.000403	0.00193	CcSEcCtD
Loratadine—Paraesthesia—Prednisolone—multiple sclerosis	0.000402	0.00193	CcSEcCtD
Loratadine—Tachycardia—Triamcinolone—multiple sclerosis	0.000402	0.00193	CcSEcCtD
Loratadine—Nausea—Azathioprine—multiple sclerosis	0.000401	0.00192	CcSEcCtD
Loratadine—Tachycardia—Methylprednisolone—multiple sclerosis	0.000401	0.00192	CcSEcCtD
Loratadine—Skin disorder—Methylprednisolone—multiple sclerosis	0.000399	0.00191	CcSEcCtD
Loratadine—Hypertension—Betamethasone—multiple sclerosis	0.000396	0.0019	CcSEcCtD
Loratadine—Hypertension—Dexamethasone—multiple sclerosis	0.000396	0.0019	CcSEcCtD
Loratadine—Asthenia—Mitoxantrone—multiple sclerosis	0.000392	0.00188	CcSEcCtD
Loratadine—Myalgia—Dexamethasone—multiple sclerosis	0.00039	0.00187	CcSEcCtD
Loratadine—Myalgia—Betamethasone—multiple sclerosis	0.00039	0.00187	CcSEcCtD
Loratadine—Discomfort—Betamethasone—multiple sclerosis	0.000385	0.00185	CcSEcCtD
Loratadine—Discomfort—Dexamethasone—multiple sclerosis	0.000385	0.00185	CcSEcCtD
Loratadine—Hypotension—Methylprednisolone—multiple sclerosis	0.000384	0.00184	CcSEcCtD
Loratadine—Pain—Prednisolone—multiple sclerosis	0.000383	0.00184	CcSEcCtD
Loratadine—Pharyngitis—Methotrexate—multiple sclerosis	0.00038	0.00182	CcSEcCtD
Loratadine—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000375	0.0018	CcSEcCtD
Loratadine—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000375	0.0018	CcSEcCtD
Loratadine—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000374	0.00179	CcSEcCtD
Loratadine—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000374	0.00179	CcSEcCtD
Loratadine—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000374	0.00179	CcSEcCtD
Loratadine—Insomnia—Triamcinolone—multiple sclerosis	0.000373	0.00179	CcSEcCtD
Loratadine—Insomnia—Methylprednisolone—multiple sclerosis	0.000372	0.00178	CcSEcCtD
Loratadine—Ill-defined disorder—Prednisone—multiple sclerosis	0.00037	0.00177	CcSEcCtD
Loratadine—Paraesthesia—Triamcinolone—multiple sclerosis	0.00037	0.00177	CcSEcCtD
Loratadine—Feeling abnormal—Prednisolone—multiple sclerosis	0.000369	0.00177	CcSEcCtD
Loratadine—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000369	0.00177	CcSEcCtD
Loratadine—Shock—Betamethasone—multiple sclerosis	0.000368	0.00176	CcSEcCtD
Loratadine—Shock—Dexamethasone—multiple sclerosis	0.000368	0.00176	CcSEcCtD
Loratadine—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000367	0.00176	CcSEcCtD
Loratadine—Nervous system disorder—Betamethasone—multiple sclerosis	0.000367	0.00176	CcSEcCtD
Loratadine—Agitation—Prednisone—multiple sclerosis	0.000367	0.00176	CcSEcCtD
Loratadine—Tachycardia—Dexamethasone—multiple sclerosis	0.000365	0.00175	CcSEcCtD
Loratadine—Tachycardia—Betamethasone—multiple sclerosis	0.000365	0.00175	CcSEcCtD
Loratadine—Angioedema—Prednisone—multiple sclerosis	0.000365	0.00175	CcSEcCtD
Loratadine—Dyspepsia—Triamcinolone—multiple sclerosis	0.000363	0.00174	CcSEcCtD
Loratadine—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000362	0.00174	CcSEcCtD
Loratadine—Malaise—Prednisone—multiple sclerosis	0.00036	0.00172	CcSEcCtD
Loratadine—Syncope—Prednisone—multiple sclerosis	0.000358	0.00172	CcSEcCtD
Loratadine—Tinnitus—Methotrexate—multiple sclerosis	0.000357	0.00171	CcSEcCtD
Loratadine—Fatigue—Triamcinolone—multiple sclerosis	0.000355	0.0017	CcSEcCtD
Loratadine—Fatigue—Methylprednisolone—multiple sclerosis	0.000355	0.0017	CcSEcCtD
Loratadine—Pain—Triamcinolone—multiple sclerosis	0.000352	0.00169	CcSEcCtD
Loratadine—Loss of consciousness—Prednisone—multiple sclerosis	0.000351	0.00168	CcSEcCtD
Loratadine—Hypotension—Dexamethasone—multiple sclerosis	0.000349	0.00167	CcSEcCtD
Loratadine—Hypotension—Betamethasone—multiple sclerosis	0.000349	0.00167	CcSEcCtD
Loratadine—Vomiting—Mitoxantrone—multiple sclerosis	0.000347	0.00166	CcSEcCtD
Loratadine—Immune system disorder—Methotrexate—multiple sclerosis	0.000346	0.00166	CcSEcCtD
Loratadine—Hypertension—Prednisone—multiple sclerosis	0.000345	0.00165	CcSEcCtD
Loratadine—Rash—Mitoxantrone—multiple sclerosis	0.000344	0.00165	CcSEcCtD
Loratadine—Dermatitis—Mitoxantrone—multiple sclerosis	0.000344	0.00165	CcSEcCtD
Loratadine—Headache—Mitoxantrone—multiple sclerosis	0.000342	0.00164	CcSEcCtD
Loratadine—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000341	0.00163	CcSEcCtD
Loratadine—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000341	0.00163	CcSEcCtD
Loratadine—Myalgia—Prednisone—multiple sclerosis	0.00034	0.00163	CcSEcCtD
Loratadine—Feeling abnormal—Triamcinolone—multiple sclerosis	0.00034	0.00163	CcSEcCtD
Loratadine—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000339	0.00162	CcSEcCtD
Loratadine—Alopecia—Methotrexate—multiple sclerosis	0.000339	0.00162	CcSEcCtD
Loratadine—Insomnia—Dexamethasone—multiple sclerosis	0.000338	0.00162	CcSEcCtD
Loratadine—Insomnia—Betamethasone—multiple sclerosis	0.000338	0.00162	CcSEcCtD
Loratadine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000337	0.00162	CcSEcCtD
Loratadine—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000336	0.00161	CcSEcCtD
Loratadine—Paraesthesia—Dexamethasone—multiple sclerosis	0.000336	0.00161	CcSEcCtD
Loratadine—Paraesthesia—Betamethasone—multiple sclerosis	0.000336	0.00161	CcSEcCtD
Loratadine—Discomfort—Prednisone—multiple sclerosis	0.000336	0.00161	CcSEcCtD
Loratadine—Dyspepsia—Dexamethasone—multiple sclerosis	0.000329	0.00158	CcSEcCtD
Loratadine—Dyspepsia—Betamethasone—multiple sclerosis	0.000329	0.00158	CcSEcCtD
Loratadine—Dysgeusia—Methotrexate—multiple sclerosis	0.000327	0.00157	CcSEcCtD
Loratadine—Body temperature increased—Triamcinolone—multiple sclerosis	0.000326	0.00156	CcSEcCtD
Loratadine—Anaphylactic shock—Prednisone—multiple sclerosis	0.000326	0.00156	CcSEcCtD
Loratadine—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000325	0.00156	CcSEcCtD
Loratadine—Nausea—Mitoxantrone—multiple sclerosis	0.000324	0.00156	CcSEcCtD
Loratadine—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000323	0.00155	CcSEcCtD
Loratadine—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000323	0.00155	CcSEcCtD
Loratadine—Fatigue—Dexamethasone—multiple sclerosis	0.000322	0.00155	CcSEcCtD
Loratadine—Fatigue—Betamethasone—multiple sclerosis	0.000322	0.00155	CcSEcCtD
Loratadine—Shock—Prednisone—multiple sclerosis	0.00032	0.00154	CcSEcCtD
Loratadine—Pain—Dexamethasone—multiple sclerosis	0.00032	0.00153	CcSEcCtD
Loratadine—Pain—Betamethasone—multiple sclerosis	0.00032	0.00153	CcSEcCtD
Loratadine—Nervous system disorder—Prednisone—multiple sclerosis	0.000319	0.00153	CcSEcCtD
Loratadine—Tachycardia—Prednisone—multiple sclerosis	0.000318	0.00152	CcSEcCtD
Loratadine—Skin disorder—Prednisone—multiple sclerosis	0.000316	0.00152	CcSEcCtD
Loratadine—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000309	0.00148	CcSEcCtD
Loratadine—Feeling abnormal—Betamethasone—multiple sclerosis	0.000308	0.00148	CcSEcCtD
Loratadine—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000308	0.00148	CcSEcCtD
Loratadine—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000306	0.00147	CcSEcCtD
Loratadine—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000306	0.00147	CcSEcCtD
Loratadine—Malaise—Methotrexate—multiple sclerosis	0.000301	0.00144	CcSEcCtD
Loratadine—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000297	0.00142	CcSEcCtD
Loratadine—Dizziness—Prednisolone—multiple sclerosis	0.000296	0.00142	CcSEcCtD
Loratadine—Asthenia—Triamcinolone—multiple sclerosis	0.000296	0.00142	CcSEcCtD
Loratadine—Body temperature increased—Dexamethasone—multiple sclerosis	0.000296	0.00142	CcSEcCtD
Loratadine—Abdominal pain—Dexamethasone—multiple sclerosis	0.000296	0.00142	CcSEcCtD
Loratadine—Abdominal pain—Betamethasone—multiple sclerosis	0.000296	0.00142	CcSEcCtD
Loratadine—Body temperature increased—Betamethasone—multiple sclerosis	0.000296	0.00142	CcSEcCtD
Loratadine—Asthenia—Methylprednisolone—multiple sclerosis	0.000295	0.00141	CcSEcCtD
Loratadine—Insomnia—Prednisone—multiple sclerosis	0.000295	0.00141	CcSEcCtD
Loratadine—Paraesthesia—Prednisone—multiple sclerosis	0.000292	0.0014	CcSEcCtD
Loratadine—Cough—Methotrexate—multiple sclerosis	0.000291	0.00139	CcSEcCtD
Loratadine—Dyspepsia—Prednisone—multiple sclerosis	0.000287	0.00137	CcSEcCtD
Loratadine—Chest pain—Methotrexate—multiple sclerosis	0.000284	0.00136	CcSEcCtD
Loratadine—Myalgia—Methotrexate—multiple sclerosis	0.000284	0.00136	CcSEcCtD
Loratadine—Rash—Prednisolone—multiple sclerosis	0.000283	0.00135	CcSEcCtD
Loratadine—Dermatitis—Prednisolone—multiple sclerosis	0.000282	0.00135	CcSEcCtD
Loratadine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000282	0.00135	CcSEcCtD
Loratadine—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000281	0.00135	CcSEcCtD
Loratadine—Fatigue—Prednisone—multiple sclerosis	0.000281	0.00135	CcSEcCtD
Loratadine—Headache—Prednisolone—multiple sclerosis	0.000281	0.00135	CcSEcCtD
Loratadine—Discomfort—Methotrexate—multiple sclerosis	0.000281	0.00134	CcSEcCtD
Loratadine—Constipation—Prednisone—multiple sclerosis	0.000278	0.00133	CcSEcCtD
Loratadine—Dizziness—Triamcinolone—multiple sclerosis	0.000273	0.00131	CcSEcCtD
Loratadine—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000272	0.0013	CcSEcCtD
Loratadine—Dizziness—Methylprednisolone—multiple sclerosis	0.000272	0.0013	CcSEcCtD
Loratadine—Feeling abnormal—Prednisone—multiple sclerosis	0.000268	0.00129	CcSEcCtD
Loratadine—Asthenia—Betamethasone—multiple sclerosis	0.000268	0.00129	CcSEcCtD
Loratadine—Asthenia—Dexamethasone—multiple sclerosis	0.000268	0.00129	CcSEcCtD
Loratadine—Nervous system disorder—Methotrexate—multiple sclerosis	0.000267	0.00128	CcSEcCtD
Loratadine—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000266	0.00128	CcSEcCtD
Loratadine—Nausea—Prednisolone—multiple sclerosis	0.000266	0.00128	CcSEcCtD
Loratadine—Skin disorder—Methotrexate—multiple sclerosis	0.000264	0.00127	CcSEcCtD
Loratadine—Vomiting—Triamcinolone—multiple sclerosis	0.000262	0.00126	CcSEcCtD
Loratadine—Vomiting—Methylprednisolone—multiple sclerosis	0.000261	0.00125	CcSEcCtD
Loratadine—Rash—Triamcinolone—multiple sclerosis	0.00026	0.00125	CcSEcCtD
Loratadine—Dermatitis—Triamcinolone—multiple sclerosis	0.00026	0.00124	CcSEcCtD
Loratadine—Rash—Methylprednisolone—multiple sclerosis	0.000259	0.00124	CcSEcCtD
Loratadine—Dermatitis—Methylprednisolone—multiple sclerosis	0.000259	0.00124	CcSEcCtD
Loratadine—Headache—Triamcinolone—multiple sclerosis	0.000258	0.00124	CcSEcCtD
Loratadine—Headache—Methylprednisolone—multiple sclerosis	0.000258	0.00123	CcSEcCtD
Loratadine—Body temperature increased—Prednisone—multiple sclerosis	0.000257	0.00123	CcSEcCtD
Loratadine—Abdominal pain—Prednisone—multiple sclerosis	0.000257	0.00123	CcSEcCtD
Loratadine—Diarrhoea—Dexamethasone—multiple sclerosis	0.000256	0.00123	CcSEcCtD
Loratadine—Diarrhoea—Betamethasone—multiple sclerosis	0.000256	0.00123	CcSEcCtD
Loratadine—Hypotension—Methotrexate—multiple sclerosis	0.000254	0.00122	CcSEcCtD
Loratadine—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000248	0.00119	CcSEcCtD
Loratadine—Dizziness—Dexamethasone—multiple sclerosis	0.000247	0.00119	CcSEcCtD
Loratadine—Dizziness—Betamethasone—multiple sclerosis	0.000247	0.00119	CcSEcCtD
Loratadine—Insomnia—Methotrexate—multiple sclerosis	0.000246	0.00118	CcSEcCtD
Loratadine—Nausea—Triamcinolone—multiple sclerosis	0.000245	0.00117	CcSEcCtD
Loratadine—Paraesthesia—Methotrexate—multiple sclerosis	0.000244	0.00117	CcSEcCtD
Loratadine—Nausea—Methylprednisolone—multiple sclerosis	0.000244	0.00117	CcSEcCtD
Loratadine—Somnolence—Methotrexate—multiple sclerosis	0.000242	0.00116	CcSEcCtD
Loratadine—Dyspepsia—Methotrexate—multiple sclerosis	0.00024	0.00115	CcSEcCtD
Loratadine—Vomiting—Betamethasone—multiple sclerosis	0.000238	0.00114	CcSEcCtD
Loratadine—Vomiting—Dexamethasone—multiple sclerosis	0.000238	0.00114	CcSEcCtD
Loratadine—Rash—Dexamethasone—multiple sclerosis	0.000236	0.00113	CcSEcCtD
Loratadine—Rash—Betamethasone—multiple sclerosis	0.000236	0.00113	CcSEcCtD
Loratadine—Dermatitis—Dexamethasone—multiple sclerosis	0.000236	0.00113	CcSEcCtD
Loratadine—Dermatitis—Betamethasone—multiple sclerosis	0.000236	0.00113	CcSEcCtD
Loratadine—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000235	0.00113	CcSEcCtD
Loratadine—Fatigue—Methotrexate—multiple sclerosis	0.000235	0.00112	CcSEcCtD
Loratadine—Headache—Betamethasone—multiple sclerosis	0.000234	0.00112	CcSEcCtD
Loratadine—Headache—Dexamethasone—multiple sclerosis	0.000234	0.00112	CcSEcCtD
Loratadine—Asthenia—Prednisone—multiple sclerosis	0.000234	0.00112	CcSEcCtD
Loratadine—Pain—Methotrexate—multiple sclerosis	0.000233	0.00112	CcSEcCtD
Loratadine—Feeling abnormal—Methotrexate—multiple sclerosis	0.000224	0.00108	CcSEcCtD
Loratadine—Diarrhoea—Prednisone—multiple sclerosis	0.000223	0.00107	CcSEcCtD
Loratadine—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000223	0.00107	CcSEcCtD
Loratadine—Nausea—Dexamethasone—multiple sclerosis	0.000222	0.00106	CcSEcCtD
Loratadine—Nausea—Betamethasone—multiple sclerosis	0.000222	0.00106	CcSEcCtD
Loratadine—Dizziness—Prednisone—multiple sclerosis	0.000215	0.00103	CcSEcCtD
Loratadine—Body temperature increased—Methotrexate—multiple sclerosis	0.000215	0.00103	CcSEcCtD
Loratadine—Abdominal pain—Methotrexate—multiple sclerosis	0.000215	0.00103	CcSEcCtD
Loratadine—Vomiting—Prednisone—multiple sclerosis	0.000207	0.000992	CcSEcCtD
Loratadine—Rash—Prednisone—multiple sclerosis	0.000205	0.000984	CcSEcCtD
Loratadine—Dermatitis—Prednisone—multiple sclerosis	0.000205	0.000983	CcSEcCtD
Loratadine—Headache—Prednisone—multiple sclerosis	0.000204	0.000978	CcSEcCtD
Loratadine—Asthenia—Methotrexate—multiple sclerosis	0.000195	0.000936	CcSEcCtD
Loratadine—Nausea—Prednisone—multiple sclerosis	0.000193	0.000927	CcSEcCtD
Loratadine—Diarrhoea—Methotrexate—multiple sclerosis	0.000186	0.000893	CcSEcCtD
Loratadine—Dizziness—Methotrexate—multiple sclerosis	0.00018	0.000863	CcSEcCtD
Loratadine—Vomiting—Methotrexate—multiple sclerosis	0.000173	0.000829	CcSEcCtD
Loratadine—Rash—Methotrexate—multiple sclerosis	0.000172	0.000823	CcSEcCtD
Loratadine—Dermatitis—Methotrexate—multiple sclerosis	0.000171	0.000822	CcSEcCtD
Loratadine—Headache—Methotrexate—multiple sclerosis	0.000171	0.000817	CcSEcCtD
Loratadine—Nausea—Methotrexate—multiple sclerosis	0.000162	0.000775	CcSEcCtD
Loratadine—CYP2C9—Biological oxidations—CYP27B1—multiple sclerosis	0.000131	0.00416	CbGpPWpGaD
Loratadine—CYP2C9—Biological oxidations—CYP24A1—multiple sclerosis	0.000131	0.00416	CbGpPWpGaD
Loratadine—CYP2D6—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.00013	0.00414	CbGpPWpGaD
Loratadine—CYP2D6—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.00013	0.00414	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—S1PR1—multiple sclerosis	0.000129	0.00412	CbGpPWpGaD
Loratadine—CYP2C9—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000129	0.00411	CbGpPWpGaD
Loratadine—CYP2C9—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000129	0.00411	CbGpPWpGaD
Loratadine—KCNH2—Hematopoietic Stem Cell Differentiation—IL6—multiple sclerosis	0.000129	0.00411	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—IL17A—multiple sclerosis	0.000122	0.00389	CbGpPWpGaD
Loratadine—HRH1—GPCRs, Class A Rhodopsin-like—GPR65—multiple sclerosis	0.000122	0.00387	CbGpPWpGaD
Loratadine—KCNH2—Neuronal System—BCHE—multiple sclerosis	0.000121	0.00386	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—CD28—multiple sclerosis	0.000119	0.00378	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—IL12B—multiple sclerosis	0.000114	0.00362	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—HLA-DPB1—multiple sclerosis	0.000113	0.00359	CbGpPWpGaD
Loratadine—HRH1—IL-4 Signaling Pathway—TYK2—multiple sclerosis	0.000112	0.00357	CbGpPWpGaD
Loratadine—HRH1—GPCRs, Class A Rhodopsin-like—CCR1—multiple sclerosis	0.000111	0.00354	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—CD40—multiple sclerosis	0.000108	0.00345	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—CTLA4—multiple sclerosis	0.000107	0.0034	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—GPR65—multiple sclerosis	0.000104	0.00332	CbGpPWpGaD
Loratadine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000103	0.00329	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—S1PR1—multiple sclerosis	9.86e-05	0.00314	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	9.77e-05	0.00311	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCR1—multiple sclerosis	9.54e-05	0.00304	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL13—multiple sclerosis	9.54e-05	0.00304	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—HLA-DQA1—multiple sclerosis	9.41e-05	0.00299	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—HLA-DQB1—multiple sclerosis	8.8e-05	0.0028	CbGpPWpGaD
Loratadine—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	8.63e-05	0.00275	CbGpPWpGaD
Loratadine—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	8.63e-05	0.00275	CbGpPWpGaD
Loratadine—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	8.51e-05	0.00271	CbGpPWpGaD
Loratadine—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	8.51e-05	0.00271	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—CD86—multiple sclerosis	8.47e-05	0.0027	CbGpPWpGaD
Loratadine—CYP2C8—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	8.4e-05	0.00267	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—IL10—multiple sclerosis	8.31e-05	0.00264	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—CD40LG—multiple sclerosis	8.31e-05	0.00264	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—IL4—multiple sclerosis	8.08e-05	0.00257	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—GPR65—multiple sclerosis	7.94e-05	0.00253	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—HLA-B—multiple sclerosis	7.9e-05	0.00251	CbGpPWpGaD
Loratadine—HRH1—IL-4 Signaling Pathway—STAT3—multiple sclerosis	7.86e-05	0.0025	CbGpPWpGaD
Loratadine—HRH1—GPCRs, Class A Rhodopsin-like—PTGER4—multiple sclerosis	7.64e-05	0.00243	CbGpPWpGaD
Loratadine—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	7.5e-05	0.00239	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—FAS—multiple sclerosis	7.45e-05	0.00237	CbGpPWpGaD
Loratadine—KCNH2—SIDS Susceptibility Pathways—IL1B—multiple sclerosis	7.42e-05	0.00236	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—IL2RA—multiple sclerosis	7.41e-05	0.00236	CbGpPWpGaD
Loratadine—HRH1—GPCRs, Class A Rhodopsin-like—CXCR3—multiple sclerosis	7.38e-05	0.00235	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—HLA-A—multiple sclerosis	7.32e-05	0.00233	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—CXCL13—multiple sclerosis	7.27e-05	0.00231	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—CCR1—multiple sclerosis	7.27e-05	0.00231	CbGpPWpGaD
Loratadine—HRH1—GPCRs, Class A Rhodopsin-like—CCR2—multiple sclerosis	7.18e-05	0.00228	CbGpPWpGaD
Loratadine—HRH1—IL-4 Signaling Pathway—MAPK1—multiple sclerosis	7.14e-05	0.00227	CbGpPWpGaD
Loratadine—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	6.9e-05	0.00219	CbGpPWpGaD
Loratadine—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	6.84e-05	0.00218	CbGpPWpGaD
Loratadine—CYP2C8—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	6.81e-05	0.00217	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	6.8e-05	0.00216	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—HLA-DRB1—multiple sclerosis	6.69e-05	0.00213	CbGpPWpGaD
Loratadine—HRH1—GPCRs, Class A Rhodopsin-like—CNR1—multiple sclerosis	6.62e-05	0.00211	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	6.54e-05	0.00208	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	6.32e-05	0.00201	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—CD80—multiple sclerosis	6.18e-05	0.00197	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	6.18e-05	0.00196	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	6.18e-05	0.00196	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	6.15e-05	0.00196	CbGpPWpGaD
Loratadine—CYP2C19—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	6.08e-05	0.00193	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	5.67e-05	0.00181	CbGpPWpGaD
Loratadine—CYP2D6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	5.59e-05	0.00178	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—S1PR1—multiple sclerosis	5.57e-05	0.00177	CbGpPWpGaD
Loratadine—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	5.54e-05	0.00176	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	5.51e-05	0.00175	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	5.51e-05	0.00175	CbGpPWpGaD
Loratadine—ABCB1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	5.5e-05	0.00175	CbGpPWpGaD
Loratadine—KCNH2—SIDS Susceptibility Pathways—TNF—multiple sclerosis	5.38e-05	0.00171	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	5.35e-05	0.0017	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—CCL3—multiple sclerosis	5.18e-05	0.00165	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	5.11e-05	0.00163	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—S1PR1—multiple sclerosis	5.06e-05	0.00161	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	5.03e-05	0.0016	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	5.03e-05	0.0016	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—PTGER4—multiple sclerosis	4.98e-05	0.00159	CbGpPWpGaD
Loratadine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	4.98e-05	0.00158	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—IFNG—multiple sclerosis	4.89e-05	0.00155	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—CXCR3—multiple sclerosis	4.81e-05	0.00153	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—RGS1—multiple sclerosis	4.74e-05	0.00151	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—CCR2—multiple sclerosis	4.68e-05	0.00149	CbGpPWpGaD
Loratadine—HRH1—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	4.62e-05	0.00147	CbGpPWpGaD
Loratadine—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	4.51e-05	0.00143	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—GPR65—multiple sclerosis	4.49e-05	0.00143	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	4.4e-05	0.0014	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—IL1B—multiple sclerosis	4.36e-05	0.00139	CbGpPWpGaD
Loratadine—KCNH2—SIDS Susceptibility Pathways—IL6—multiple sclerosis	4.34e-05	0.00138	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—IL2—multiple sclerosis	4.34e-05	0.00138	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—CNR1—multiple sclerosis	4.32e-05	0.00137	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—RGS1—multiple sclerosis	4.3e-05	0.00137	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	4.3e-05	0.00137	CbGpPWpGaD
Loratadine—ABCB1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	4.17e-05	0.00133	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—CXCL13—multiple sclerosis	4.11e-05	0.00131	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—CCR1—multiple sclerosis	4.11e-05	0.00131	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—GPR65—multiple sclerosis	4.08e-05	0.0013	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	3.96e-05	0.00126	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—LINGO1—multiple sclerosis	3.94e-05	0.00125	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—SRM—multiple sclerosis	3.9e-05	0.00124	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—CXCL10—multiple sclerosis	3.89e-05	0.00124	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—CXCL13—multiple sclerosis	3.73e-05	0.00119	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—CCR1—multiple sclerosis	3.73e-05	0.00119	CbGpPWpGaD
Loratadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—multiple sclerosis	3.72e-05	0.00118	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	3.68e-05	0.00117	CbGpPWpGaD
Loratadine—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	3.66e-05	0.00116	CbGpPWpGaD
Loratadine—CYP2C8—Biological oxidations—POMC—multiple sclerosis	3.62e-05	0.00115	CbGpPWpGaD
Loratadine—KCNH2—Neuronal System—MAPK1—multiple sclerosis	3.55e-05	0.00113	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—SRM—multiple sclerosis	3.48e-05	0.00111	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—TAGAP—multiple sclerosis	3.42e-05	0.00109	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—SRM—multiple sclerosis	3.4e-05	0.00108	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—TGFB1—multiple sclerosis	3.39e-05	0.00108	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—CCL5—multiple sclerosis	3.35e-05	0.00107	CbGpPWpGaD
Loratadine—ABCB1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	3.3e-05	0.00105	CbGpPWpGaD
Loratadine—CYP2C19—Biological oxidations—POMC—multiple sclerosis	3.23e-05	0.00103	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—SRM—multiple sclerosis	3.2e-05	0.00102	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—SRM—multiple sclerosis	3.18e-05	0.00101	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—TNF—multiple sclerosis	3.16e-05	0.00101	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	3.1e-05	0.000985	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	3.03e-05	0.000964	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—CCR5—multiple sclerosis	3.02e-05	0.00096	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—S1PR1—multiple sclerosis	2.99e-05	0.000951	CbGpPWpGaD
Loratadine—CYP2D6—Biological oxidations—POMC—multiple sclerosis	2.97e-05	0.000945	CbGpPWpGaD
Loratadine—CYP2C9—Biological oxidations—POMC—multiple sclerosis	2.94e-05	0.000937	CbGpPWpGaD
Loratadine—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	2.91e-05	0.000927	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—GPC5—multiple sclerosis	2.91e-05	0.000925	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—PTGER4—multiple sclerosis	2.82e-05	0.000896	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—CYP27B1—multiple sclerosis	2.75e-05	0.000875	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—CYP24A1—multiple sclerosis	2.75e-05	0.000875	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—CXCR3—multiple sclerosis	2.72e-05	0.000865	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.69e-05	0.000855	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—CCL3—multiple sclerosis	2.66e-05	0.000845	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—CCR2—multiple sclerosis	2.65e-05	0.000842	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—PTGER4—multiple sclerosis	2.56e-05	0.000814	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—RGS1—multiple sclerosis	2.54e-05	0.000808	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—GPC5—multiple sclerosis	2.52e-05	0.0008	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—CXCR3—multiple sclerosis	2.47e-05	0.000786	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—CYP27B1—multiple sclerosis	2.46e-05	0.000781	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—CYP24A1—multiple sclerosis	2.46e-05	0.000781	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—CNR1—multiple sclerosis	2.44e-05	0.000777	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—GPR65—multiple sclerosis	2.41e-05	0.000766	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—CCR2—multiple sclerosis	2.4e-05	0.000764	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.4e-05	0.000763	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—CYP27B1—multiple sclerosis	2.4e-05	0.000762	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—CYP24A1—multiple sclerosis	2.4e-05	0.000762	CbGpPWpGaD
Loratadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	2.37e-05	0.000752	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—POMC—multiple sclerosis	2.36e-05	0.00075	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—CCL2—multiple sclerosis	2.31e-05	0.000734	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	2.26e-05	0.000718	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	2.26e-05	0.000718	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—GPC5—multiple sclerosis	2.25e-05	0.000714	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	2.24e-05	0.000712	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	2.24e-05	0.000712	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—CNR1—multiple sclerosis	2.22e-05	0.000706	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—CCR1—multiple sclerosis	2.2e-05	0.000701	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—CXCL13—multiple sclerosis	2.2e-05	0.000701	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—CXCL10—multiple sclerosis	2.2e-05	0.000699	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—GPC5—multiple sclerosis	2.19e-05	0.000697	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.19e-05	0.000696	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—SRM—multiple sclerosis	2.1e-05	0.000667	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—RRM1—multiple sclerosis	2.08e-05	0.000663	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—GPC5—multiple sclerosis	2.07e-05	0.000657	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—GPC5—multiple sclerosis	2.05e-05	0.000651	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—CXCL10—multiple sclerosis	2e-05	0.000635	CbGpPWpGaD
Loratadine—CYP3A4—Biological oxidations—POMC—multiple sclerosis	1.94e-05	0.000618	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—CCL5—multiple sclerosis	1.89e-05	0.000602	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—RRM1—multiple sclerosis	1.86e-05	0.000592	CbGpPWpGaD
Loratadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	1.82e-05	0.000578	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—RRM1—multiple sclerosis	1.82e-05	0.000578	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—CCL5—multiple sclerosis	1.72e-05	0.000547	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—RRM1—multiple sclerosis	1.71e-05	0.000544	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—CCR5—multiple sclerosis	1.71e-05	0.000542	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—RRM1—multiple sclerosis	1.7e-05	0.00054	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—IL2RA—multiple sclerosis	1.68e-05	0.000535	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	1.68e-05	0.000533	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	1.67e-05	0.000532	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	1.64e-05	0.000521	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.62e-05	0.000514	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—CCL3—multiple sclerosis	1.57e-05	0.000499	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	1.56e-05	0.000497	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—CCR5—multiple sclerosis	1.55e-05	0.000493	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—IL2RA—multiple sclerosis	1.53e-05	0.000486	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—PTGER4—multiple sclerosis	1.51e-05	0.000481	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—PGR—multiple sclerosis	1.49e-05	0.000473	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.48e-05	0.00047	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.48e-05	0.00047	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—CXCR3—multiple sclerosis	1.46e-05	0.000464	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—CD28—multiple sclerosis	1.45e-05	0.00046	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.44e-05	0.000459	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—CCR2—multiple sclerosis	1.42e-05	0.000452	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.39e-05	0.000442	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.35e-05	0.00043	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—POMC—multiple sclerosis	1.33e-05	0.000424	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.32e-05	0.000419	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—CNR1—multiple sclerosis	1.31e-05	0.000417	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.27e-05	0.000403	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.24e-05	0.000395	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—POMC—multiple sclerosis	1.21e-05	0.000385	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—BCHE—multiple sclerosis	1.2e-05	0.000381	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—CCL2—multiple sclerosis	1.18e-05	0.000377	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—CXCL10—multiple sclerosis	1.18e-05	0.000375	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.13e-05	0.00036	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.13e-05	0.00036	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.12e-05	0.000356	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—TYK2—multiple sclerosis	1.08e-05	0.000342	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—BCHE—multiple sclerosis	1.07e-05	0.00034	CbGpPWpGaD
Loratadine—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.05e-05	0.000334	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—BCHE—multiple sclerosis	1.04e-05	0.000332	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—CD86—multiple sclerosis	1.03e-05	0.000328	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.03e-05	0.000328	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—CCL5—multiple sclerosis	1.02e-05	0.000323	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—IL2—multiple sclerosis	9.85e-06	0.000313	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—BCHE—multiple sclerosis	9.83e-06	0.000313	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—BCHE—multiple sclerosis	9.74e-06	0.00031	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—SPP1—multiple sclerosis	9.4e-06	0.000299	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—CCR5—multiple sclerosis	9.15e-06	0.000291	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—IL2RA—multiple sclerosis	9.02e-06	0.000287	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—IL2—multiple sclerosis	8.95e-06	0.000285	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—APOE—multiple sclerosis	8.32e-06	0.000265	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—CD80—multiple sclerosis	7.52e-06	0.000239	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—APOE—multiple sclerosis	7.2e-06	0.000229	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—POMC—multiple sclerosis	7.15e-06	0.000227	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—CCL2—multiple sclerosis	6.99e-06	0.000223	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—MAPK1—multiple sclerosis	6.84e-06	0.000218	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—APOE—multiple sclerosis	6.43e-06	0.000205	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—BCHE—multiple sclerosis	6.43e-06	0.000204	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—TYK2—multiple sclerosis	6.35e-06	0.000202	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—APOE—multiple sclerosis	6.27e-06	0.0002	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—POMC—multiple sclerosis	6.19e-06	0.000197	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—APOE—multiple sclerosis	5.91e-06	0.000188	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—APOE—multiple sclerosis	5.86e-06	0.000186	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—ALB—multiple sclerosis	5.64e-06	0.000179	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—POMC—multiple sclerosis	5.52e-06	0.000176	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—POMC—multiple sclerosis	5.39e-06	0.000171	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—IL2—multiple sclerosis	5.29e-06	0.000168	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—IL6—multiple sclerosis	5.26e-06	0.000167	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—POMC—multiple sclerosis	5.08e-06	0.000162	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—POMC—multiple sclerosis	5.04e-06	0.00016	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—ALB—multiple sclerosis	5.04e-06	0.00016	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—MMP9—multiple sclerosis	5e-06	0.000159	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—ALB—multiple sclerosis	4.91e-06	0.000156	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—ALB—multiple sclerosis	4.63e-06	0.000147	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—ALB—multiple sclerosis	4.59e-06	0.000146	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—STAT3—multiple sclerosis	4.45e-06	0.000141	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—MYC—multiple sclerosis	4.13e-06	0.000131	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—TGFB1—multiple sclerosis	4.12e-06	0.000131	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—MAPK1—multiple sclerosis	4.04e-06	0.000129	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—APOE—multiple sclerosis	3.87e-06	0.000123	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—POMC—multiple sclerosis	3.32e-06	0.000106	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—IL6—multiple sclerosis	3.11e-06	9.88e-05	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—ALB—multiple sclerosis	3.03e-06	9.63e-05	CbGpPWpGaD
